ReviewDrugs2006
Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes.
Review in Drugs, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Genital herpes: oral antiviral treatments.BMJ clinical evidence · 2015Pooled it
- Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children.Antimicrobial agents and chemotherapy · 2010Trial
- Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.Antimicrobial agents and chemotherapy · 2009Trial
- Effect of famciclovir combined with nerve block on acute pain in patients with herpes zoster.American journal of translational research · 2026Article
- Review
- Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus.Antimicrobial agents and chemotherapy · 2021Article
- Current Antivirals and Novel Botanical Molecules Interfering With Herpes Simplex Virus Infection.Frontiers in microbiology · 2020Review
- Article
- Optimal management of genital herpes: current perspectives.Infection and drug resistance · 2016Review
- Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.Reviews in medical virology · 2013Review
- Estimates of the pharmacokinetics of famciclovir and its active metabolite penciclovir in young Asian elephants (Elephas maximus).American journal of veterinary research · 2012Article
- Current management and recommendations for access to antiviral therapy of herpes labialis.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2012Review
- Safety of antiviral medication for the treatment of herpes during pregnancy.Canadian family physician Medecin de famille canadien · 2011Article
- Alteration of the carbohydrate for deoxyguanosine analogs markedly changes DNA replication fidelity, cell cycle progression and cytotoxicity.Mutation research · 2010Article
- Inflation and long-term maintenance of CD8 T cells responding to a latent herpesvirus depend upon establishment of latency and presence of viral antigens.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- Single-day treatment for orolabial and genital herpes: a brief review of pathogenesis and pharmacology.Therapeutics and clinical risk management · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Famciclovir (Famvir) is the oral prodrug of penciclovir, an agent that has demonstrated antiviral activity against herpes simplex viruses, type 1 (HSV-1) and 2 (HSV-2) [which cause orolabial and/or genital herpes simplex], and against varicella zoster virus (VZV) [a reactivation of which leads to herpes zoster]. Famciclovir has efficacy similar to that of aciclovir (in immunocompetent or immunocompromised patients) or valaciclovir (in immunocompetent patients) in the treatment of herpes zoster, and efficacy similar to aciclovir in the treatment of first or recurrent episodes of genital herpes (in immunocompetent or immunocompromised patients). Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients. As such, famciclovir is a well tolerated first-line option for the treatment of herpes zoster and the treatment and suppression of genital herpes, and is approved for the treatment of recurrent orolabial herpes. Convenient patient-initiated single-day (for recurrent genital herpes) and single-dose (for orolabial herpes) dosage regimens may contribute to treatment compliance, patient acceptability and subsequent treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.